Abstract | INTRODUCTION: MATERIALS AND METHODS: This study enrolled 100 patients with Union for International Cancer Control (UICC) stages I-IV biliary tract cancer who underwent surgical resection, including 16 who received sequential adjuvant chemotherapy with gemcitabine or S-1. Overall survival (OS), disease-free survival (DFS), and prognostic factors were analyzed. RESULTS: The median duration of follow-up was 12.6 months. Forty-one patients had lymph node metastasis and 81 underwent RO resection. The 1-, 3-, and 5-year OS rates were 80.9%, 48.6%, and 38.3%, respectively, and the 1-, 3-, and 5-year DFS rates were 59.8%, 39.9%, and 24.9%, respectively. Five-year OS rates were similar in patients who did (40.4%) and did not (32.4%) receive adjuvant chemotherapy. The morbidity and mortality rates were 59% and 3%, respectively. Multivariate analysis showed that only lymph node metastasis (p = 0.042) was independently associated with long-term survival. CONCLUSIONS:
|
Authors | Noboru Harada, Ken Shirabe, Tomoharu Yoshizumi, Toru Ikegami, Hideaki Uchiyama, Yuji Soejima, Yo-Ichi Yamashita, Hiroshi Saeki, Eiji Oki, Hirofumi Kawanaka, Masaru Morita, Tetsuo Ikeda, Hiroshi Matsuura, Kenichiro Okadome, Yoshihiko Maehara |
Journal | Fukuoka igaku zasshi = Hukuoka acta medica
(Fukuoka Igaku Zasshi)
Vol. 104
Issue 12
Pg. 539-48
(Dec 2013)
ISSN: 0016-254X [Print] Japan |
PMID | 24693682
(Publication Type: Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Drug Combinations
- Deoxycytidine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
(administration & dosage)
- Biliary Tract Neoplasms
(drug therapy, mortality, pathology, surgery)
- Biliary Tract Surgical Procedures
- Chemotherapy, Adjuvant
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- Drug Combinations
- Female
- Humans
- Lymphatic Metastasis
- Male
- Middle Aged
- Multivariate Analysis
- Oxonic Acid
(administration & dosage)
- Tegafur
(administration & dosage)
- Time Factors
- Treatment Outcome
- Gemcitabine
|